Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

Perspective - Journal of Medical Oncology and Therapeutics (2023) Volume 8, Issue 2

Monoclonal antibodies: A powerful tool in medicine

Yoshika Fengchun*

Department of Oncology, Inoue Hospital, Osaka, Japan

*Corresponding Author:
Yoshika Fengchun
Department of Oncology
Inoue Hospital, Osaka, Japan
E-mail: yosh@feng.eonet.ne.jp

Received: 02-Mar-2023, Manuscript No. JMOT-23-91124; Editor assigned: 03-Mar-2023, PreQC No. JMOT-23-91124(PQ); Reviewed: 17-Mar-2023, QC No. JMOT-23-91124; Revised: 20-Mar-2023, Manuscript No. JMOT-23-91124(R); Published: 27-Mar-2023, DOI: 10.35841/jmot-8.2.139

Citation: Fengchun Y. Monoclonal antibodies: A powerful tool in medicine. J Med Oncl Ther. 2023;8(2):139

Visit for more related articles at Journal of Medical Oncology and Therapeutics

Monoclonal antibodies (mAbs) are laboratory-made molecules that mimic the immune system's ability to fight off harmful pathogens such as bacteria, viruses, and cancer cells. These antibodies are highly specific and bind to a single target antigen, making them a powerful tool in medicine for diagnosing and treating a wide range of diseases. The process of producing monoclonal antibodies involves using laboratory mice to produce hybridomas. Hybridomas are cells created by fusing a mouse B-cell (which produces antibodies) with a cancer cell that grows indefinitely in culture. The resulting hybridomas can produce large quantities of a single type of antibody, which is identical to the antibody produced by the original B-cell [1].

After the hybridomas are created, the antibody-producing cells are isolated and grown in culture, producing large quantities of the monoclonal antibody. These antibodies are then purified and used in various diagnostic and therapeutic applications. Monoclonal antibodies have revolutionized the field of medicine and have numerous applications in both diagnostics and therapeutics. One of the most significant applications of monoclonal antibodies is in diagnostics. These antibodies can be used to detect the presence of specific molecules, known as antigens, in a patient's blood or tissues. This makes them useful for identifying infections, autoimmune diseases, and even cancer. For example, the monoclonal antibody PSA (prostatespecific antigen) is used to detect prostate cancer in men. The antibody binds specifically to PSA, which is produced by prostate cancer cells, allowing doctors to diagnose the disease early and accurately [2].

Monoclonal antibodies are also used in therapeutics, where they are used to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. These antibodies work by targeting specific antigens on the surface of diseased cells, which can either destroy the cells directly or trigger an immune response that helps the body fight the disease. Monoclonal antibodies have become an important part of cancer treatment. Many of these antibodies are designed to target specific antigens that are overexpressed on cancer cells, making them a promising treatment option for certain types of cancer. For example, trastuzumab (Herceptin) is a monoclonal antibody that targets the HER2 protein, which is overexpressed in about 20% of breast cancers. When trastuzumab binds to HER2, it blocks the signal that promotes cancer cell growth and survival, leading to tumor regression [3].

Monoclonal antibodies are also used to treat autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

These antibodies target specific molecules in the immune system that are responsible for causing inflammation and tissue damage. For example, adalimumab (Humira) is a monoclonal antibody that targets a protein called tumor necrosis factoralpha (TNF-alpha), which is overproduced in autoimmune disorders such as rheumatoid arthritis. By blocking TNFalpha, adalimumab can reduce inflammation and relieve symptoms of the disease. Monoclonal antibodies are also being explored as a potential treatment for infectious diseases, including COVID-19. These antibodies can neutralize the virus by binding to the spike protein on the surface of the virus, preventing it from infecting human cells. Several monoclonal antibodies have been authorized for emergency use by the U.S. Food and Drug Administration (FDA) to treat COVID-19, including bamlanivimab and casirivimab/ imdevimab [4].

One challenge is that the production of monoclonal antibodies can be expensive and time-consuming. It can take several months to produce a single batch of monoclonal antibodies, and the process involves complex laboratory techniques and equipment. Another challenge is that monoclonal antibodies can cause side effects, such as allergic reactions and infusion reactions. This is because the antibodies are foreign to the body and can trigger an immune response. However, these side effects are usually mild and can be managed with medication. There are also limitations to the use of monoclonal antibodies in certain diseases. For example, not all cancer cells express specific antigens that can be targeted by monoclonal antibodies, making them ineffective in some cases. Additionally, some viruses, such as HIV, mutate rapidly, making it difficult to develop effective monoclonal antibodies.

Despite these challenges and limitations, monoclonal antibodies continue to be a promising area of research in medicine. Researchers are exploring new ways to produce monoclonal antibodies more efficiently and cost-effectively, using technologies such as phage display and yeast display. There is also growing interest in using monoclonal antibodies as a preventive measure, such as in the form of vaccines. Researchers are developing monoclonal antibody vaccines that can stimulate the immune system to produce specific antibodies that can protect against infectious diseases. Finally, researchers are also exploring the potential of using monoclonal antibodies to target other molecules in the body, such as enzymes and growth factors. This could lead to new treatments for a wide range of diseases, including cancer and metabolic disorders [5].

Monoclonal antibodies have revolutionized the field of medicine and have become a powerful tool in both diagnostics and therapeutics. These laboratory-made molecules can be highly specific and effective at targeting specific antigens in the body, making them useful for identifying and treating a wide range of diseases. While there are challenges and limitations to their use, ongoing research is exploring new ways to produce and use monoclonal antibodies in medicine. As the technology advances, it is likely that monoclonal antibodies will continue to play a significant role in improving human health and treating disease.

References

  1. Ladhani HA, Yowler CJ, Claridge JA. Burn wound colonization, infection, and sepsis. Surg Infect. 2021;22(1):44-8.

    2. Indexed at, Google Scholar, Cross Ref

  2. Suresh K, Naidoo J, Lin CT, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: Benefits and pulmonary toxicities. Chest. 2018;154(6):1416-23.

    3. Indexed at, Google Scholar, Cross Ref

  3. Hou C, Chen L, Yang L et al. An insight into anti-inflammatory effects of natural polysaccharides. Int J Biol Macromol. 2020;153:248-55.

    4. Indexed at, Google Scholar, Cross Ref

  4. Lana JF, Lana AV, Rodrigues QS, et al. Nebulization of glutathione and N-Acetylcysteine as an adjuvant therapy for COVID-19 onset. Adv Redox Res. 2021;3:100015.

    5. Indexed at, Google Scholar, Cross Ref

  5. Yanez M, Blanchette J, Jabbarzadeh E. Modulation of inflammatory response to implanted biomaterials using natural compounds. Curr Pharm Des. 2017;23(41):6347-57.

    6. Indexed at, Google Scholar, Cross Ref

Get the App